Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-99
SponsorMarc de Perrot
About this trial
The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery.
Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.
Eligibility criteria
Qualifiers
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Age > 18 years at time of study entry.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Body weight >30 kg
Disqualifiers
Participation in another clinical study with an investigational product during the last 8 weeks before enrollment
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
Known oncogenic driver mutations such as EGFR mutant or ALK mutant
The presence of N3 disease in the contralateral mediastinum, contralateral hilum, or contralateral supraclavicular lymph node confirmed histologically.
Trial design
Treatments tested in this trial
- Durvalumab
- Non-ablative oligofractionated radiation (NORT)
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Marc de Perrot
Lead sponsor
University Health Network, Toronto
Sponsor institution
Ozmosis Research Inc.
Collaborator
Source ClinicalTrials.gov